Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
AssigneeLudwig Institute for Cancer Research
InventorsAlan Townsend, Judy Bastin, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Thomas Gajewski
Life of this patent
Estimating the term…
Abstract
Tumor rejection antigens derived from MAGE tumor rejection precursors have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
Claims7
Method for activating cytolytic T cells, comprising contacting said cytolytic T cells with a combination of IL-6 and IL-12 and a tumor rejection antigen, the amino acid sequence of which is set forth at SEQ ID NO:
- 6 in an amount sufficient to activate said cytolytic T cells.
Non-covalently associated composition of matter consisting essentially of IL-6, IL-12 and a tumor rejection antigen, the amino acid sequence of which is set forth at SEQ ID NO:
- 6, in an amount sufficient to stimulate cytolytic T cells.
Kit useful in activating cytolytic T cells, comprising a separate portion of each of (i) IL-6, (ii) IL-12, and (iii) a tumor rejection antigen, the amino acid sequence of which is set forth at SEQ ID NO:
- 6, or a DNA molecule which encodes said tumor rejection antigen, and a container means for holding separate the portions of (i), (ii) and (iii).
Dependencies are inferred from the claim text.